SNYSanofi-Aventis
$43.75
$0.23
(0.52%)
Closed $43.75
$0.01
(0.02%)
After Hours
EarningsJul 30
Mkt Cap$105.19B
Vol2.19M
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
Breakthrough drugs, AI-powered technologies, and soaring global demand are driving one of healthcare’s fastest-growing markets New York, NY – July 21, 2026 – Market News Updates News Commentary – Diabetes care is going through one of its biggest transformations in decades. Instead of simply helping patients keep their blood sugar under control, today’s therapies […]
The post Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities appeared first on Financial News Media.
Financial News Media
Trump's first-term policies helped lower some insulin costs: HHS report
A new study from the Department of Health and Human Services shows that policies in President Donald Trump's first administration helped lower some patients' insulin costs below $35 for a 30-day supply.FOX Business obtained a copy of the new report set to be released as early as Monday. It shows...
FOXBusiness.com - Business/Financial
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.read more...
Benzinga
Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug
FDA approves Sanofi's Sarclisa Escena, the first subcutaneous multiple myeloma treatment administered via a hands-free on-body injector.read more...
Benzinga
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Zacks
R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy
R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy...
Yahoo! Finance: News
Snowflake Gains 6% in a Month: Should You Buy, Sell, or Hold the Stock?
SNOW's platform adoption and AI momentum are fueling gains, but rising competition, margin pressure, and premium valuation keep investors cautious.
Zacks
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Zacks
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Zacks
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints
Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.read more...
Benzinga
<
1
2
...
>
Advertisement|Remove ads.
Latest SNY News
ViewNext-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
Financial News Media
Trump's first-term policies helped lower some insulin costs: HHS report
FOXBusiness.com - Business/Financial
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Benzinga
Advertisement|Remove ads.